CYTK · Cytokinetics Inc

Track CYTK — free

$65.91 +0.27 (+0.41%) At close · Sep 30

S&P 400 member Russell 2000 member Rebalance outlook locked

Market Cap

$9.20B

139.02M

Volume · Sep 30 2.98M Avg daily vol (3M) 1.92M

Up next

Next earnings call

Nov 6, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 6, 2026

Q2 2026 earnings call transcript

call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

+21.8%

Trailing year

Short interest

12.6%

Latest settlement · 10.6 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026

Q2 FY26

TL;DR. Cytokinetics reported strong early Myqorzo launch momentum with Q2 U.S. net product revenue of $23.0M and 1,500 patients dispensed, alongside positive ACACIA-HCM Phase 3 results supporting a planned Q4 sNDA for non-obstructive HCM, while SG&A spend and full-year GAAP expense guidance were raised and net loss widened to $198.8M.

Bullish

+ Myqorzo Q2 U.S. net product revenue reached $23.0M with 1,500 patients dispensed, ~tripling Q1
+ New-to-brand CMI category share reached >40% exit share in Q2 with aspirations for >50% by year-end
+ ACACIA-HCM Phase 3 in NHCM met both dual primary endpoints (KCCQ CSS and peak VO2) with no new safety signals
+ Balance sheet fortified to ~$1.7B in cash/investments via $760M public offering in May 2026
+ International access expanded with Germany launch, UK MHRA approval/NICE recommendation, and Netherlands reimbursement

Bearish

− Full-year 2026 GAAP combined R&D + SG&A guidance raised to $860–$890M (from $830–$870M)
− Cost of goods sold of $2.7M driven by a non-routine charge related to drug supply optimization

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Neutral Sentiment Neutral Fundamentals Poor Quant / Vol Moderate

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −6%

below

Price vs 50-day avg −11%

below

RSI (14) 34

neutral

MACD trend Negative

52-week position 34%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Neutral

1-month return −8%

trailing

6-month return +2%

trailing

YTD return +4%

this year

Relative strength −10%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $74 › 200d $70 — 50d above 200d

Institutional flow Accumulating

+8% holders QoQ · +91 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

12.57% of float · ▲ +0.2% MoM · 10.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

489 holders — near 3-yr high, broad support

Squeeze score 67

elevated · 0–100

Fundamentals

Poor

Revenue growth −87%

Y/Y

EPS growth −24%

Y/Y

Free cash flow $-534.8M

Balance sheet $165.0M

net debt

Quant / Vol

risk profile

Moderate

Volatility 44%

annualized · 1-yr

Max drawdown −26%

past year

ATR 3.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 2 of last 2

Latest guidance · from the 8-K filed Aug 6, 2026

GAAP combined R&D and SG&A Expense · full year 2026 GAAP Initiated $860M – $890M

Guided vs delivered · last 2 settled

Revenue 2024

guided $3M – $5M

guided $3M – $5M $18.47M Beat +361.9%

Revenue 2021

guided $23M – $28M

guided $23M – $28M $70.43M Beat +176.2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−6% Bearish

Price vs 50-day avg

−11% Bearish

RSI (14)

34 Neutral

MACD trend

Negative Bearish

52-week position

34% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $74 › 200d $70 — 50d above 200d

Institutional flow Accumulating

+8% holders QoQ · +91 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

12.57% of float · ▲ +0.2% MoM · 10.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

489 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $55 Now $66 · 34% Range high $87

vs 200-day avg -6% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CYTK Cytokinetics Inc this stock	$9.20B	+3.7%	-87.4%	—	12.6%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+15.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-1.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+553.0%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

489

% held: 120.7%
Net QoQ: +11.1M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

547

View

Short & Settlement

Short Interest Rising

Shares short

17.5M

Days to cover: 10.6d
Change: +39.0K sh

View

Short Volume

Short vol %

54%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

98.0K

Value: $7.2M
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

46.7%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Buy

Member

Gilbert Cisneros

Amount: $1.0K–$15.0K
Traded: Jun 30, 2026

View

Financials

Revenue (FY)

$88.0M

Net income (FY): $-785.0M
EPS diluted: $-6.54

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 14, 2026
This year: 18

View

Proposed Sales

Value

$147.2K

Shares: 2.0K
Filed: Sep 11, 2026

View

Earnings & Events

Earnings Calls

Last call

Sep 14, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
CYTK	+0.2%	-7.7%	+2.0%	-7.1%	+3.7%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	+0.8%	-7.8%	-10.1%	-6.5%	-8.1%

Key facts CIK 1061983 CUSIP 23282W605 13F (30d) 13 filings 12 filers Visit website Investor relations

CYTK · Cytokinetics Inc

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance